{
    "clinical_study": {
        "@rank": "152931", 
        "arm_group": [
            {
                "arm_group_label": "A: Vismodegib", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "B: Rabeprazole + Vismodegib", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "C: Itraconazole + Vismodegib", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "D: Fluconazole + Vismodegib", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, open-label, 4-arm, multiple-dose study will  evaluate the effec t of\n      coadministration of a protein pump inhibitor, an inhibitor of P-glycoprotei n and CYP3A4, or\n      an inhibitor of CYP2C9 on the pharmacokinetics of vismodegib  i n healthy female subjects of\n      non-childbearing potential. Subjects will be random ized to receive multiple oral doses of\n      vismodegib, alone or in combination with multiple oral doses of either rabeprazole,\n      itraconazole or fluconazole. Anticipa ted time on study treatment is up to 11 days."
        }, 
        "brief_title": "A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females of non-childbearing potential\n\n          -  Body mass index (BMI) 18 to 32 kg/m2, inclusive\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, physical examination. 12-lead ECG, and vital signs\n\n          -  Clinical laboratory evaluations, complete blood count and urinalysis within the\n             normal range for the test laboratory, unless not deemed clinically significant by the\n             investigator\n\n          -  Negative test for drugs of abuse at screening and check-in (including alcohol)\n\n          -  Negative for hepatitis B, hepatitis C and HIV infection\n\n          -  Non-childbearing potential is defined as: non-pregnant, non-lactating, and either\n             postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy\n             and/or hysterectomy)\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical evidence of any metabolic (including type 1 or 2\n             diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary,\n             cardiovascular, endocrine, GI (including gastric or duodenal ulcers),\n             Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or\n             psychiatric disorder\n\n          -  History of inflammatory arthritis\n\n          -  History of symptomatic hypotension\n\n          -  History of seizure disorders\n\n          -  History of bipolar or major depressive disorder\n\n          -  History of stomach or intestinal surgery or resection that would potentially alter\n             absorption and/or excretion of orally administered drugs (appendectomy, hernia\n             repair, and/or cholecystectomy will be allowed)\n\n          -  History of alcoholism or drug addiction within 1 year prior to check-in\n\n          -  Use of any tobacco- or nicotine-containing products within 6 months prior to check-in\n\n          -  Participation in any other investigational study drug or biological agent trial in\n             which receipt of investigational study drug occurred within 5 half-lives or 30 days,\n             whichever is longer, prior to check-in\n\n          -  Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in\n\n          -  History of chronic PPI use (> 30 days of continuous daily dosing) within 6 months of\n             check-in"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772290", 
            "org_study_id": "GP28465"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A: Vismodegib", 
                    "B: Rabeprazole + Vismodegib", 
                    "C: Itraconazole + Vismodegib", 
                    "D: Fluconazole + Vismodegib"
                ], 
                "description": "Multiple oral doses", 
                "intervention_name": "vismodegib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B: Rabeprazole + Vismodegib", 
                "description": "Multiple oral doses", 
                "intervention_name": "rabeprazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C: Itraconazole + Vismodegib", 
                "description": "Multiple oral doses", 
                "intervention_name": "itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "D: Fluconazole + Vismodegib", 
                "description": "Multiple oral doses", 
                "intervention_name": "fluconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Itraconazole", 
                "Hydroxyitraconazole", 
                "Rabeprazole", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daytona Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32117"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75247"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Relative effect of rabeprazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)", 
                "safety_issue": "No", 
                "time_frame": "up to 12 days"
            }, 
            {
                "measure": "Relative effect of itraconazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)", 
                "safety_issue": "No", 
                "time_frame": "up to 12 days"
            }, 
            {
                "measure": "Relative effect of fluconazole on the steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)", 
                "safety_issue": "No", 
                "time_frame": "up to 12 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772290"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}